Failure of propranolol to inhibit the epinephrine-induced enhancement of responses to sympathetic nerve stimulation in the rat mesenteric vascular bed

Experiments were designed to characterize the nature of the epinephrine-induced potentiation of responses to sympathetic nerve stimulation in the Hooded Wistar rat. The responses to sympathetic nerve stimulation were determined in the isolated perfused mesenteric vascular bed preparation before and after infusion of epinephrine (at 0.27 or 2.7 microM); at the conclusion of the experiment the content of epinephrine in the mesenteric artery was determined. The intraluminal infusion of epinephrine at both high and low concentrations potentiated the responses of the preparation to sympathetic nerve stimulation. Mesenteric artery concentrations of this catecholamine were unchanged at the lower concentration (0.27 microM), but were increased after perfusion of epinephrine at the higher concentration (2.7 microM). The beta adrenoceptor antagonist propranolol (0.5 microM) did not prevent the epinephrine-associated potentiation of responses to sympathetic nerve stimulation, nor did it influence the pressor effects of exogenous norepinephrine. The results suggest that beta adrenoceptors do not play a role in the epinephrine-induced potentiation of responses to sympathetic nerve stimulation in the rat mesenteric vascular bed preparation. This potentiation may, however, be related to a desensitization of presynaptic inhibitory alpha adrenoceptors.     

Rat jugular vein relaxes to norepinephrine, phenylephrine and histamine.

Circular muscle of the rat external jugular vein contracted to serotonin, angiotensin and potassium chloride but not to norepinephrine, phenylephrine, histamine or carbamylcholine. In contrast, rabbit and guinea-pig jugular veins contracted to norepinephrine, phenylephrine and histamine, although contractions to norepinephrine were small in guinea-pig jugular veins. Norepinephrine, phenylephrine and histamine produced a concentration-dependent sustained relaxation of serotonin-induced contractions in the rat jugular vein, as did isoproterenol, nitroglycerin and papaverine. Propranolol blocked relaxation to norepinephrine, phenylephrine and isoproterenol whereas metiamide, a H2 receptor antagonist blocked relaxation to histamine. alpha adrenergic receptor blockade with phentolamine or prazosin resulted in greater relaxation to norepinephrine whereas cocaine did not enhance norepinephrine-induced vasodilation. This study supports the premise that norepinephrine may exert prominent beta adrenergic receptor stimulation in some blood vessels and that this effect may be more apparent in veins than arteries.     

Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats.

Effects of pimobendan (PBD) were investigated on isolated rat blood vessels. PBD dose-dependently relaxed aortic, femoral arterial and mesenteric venous preparations precontracted with KCl and reduced the amplitude of spontaneous contractions of portal venous preparations; the sensitivity to PBD was femoral greater than portal greater than mesenteric greater than aorta. Relaxation response of the femoral artery to PBD was not changed by propranolol and aminophylline. Glyceryl trinitrate (GTN), isoproterenol (ISO), forskolin and adenosine also elicited dose-dependent relaxations of femoral arteries; the rank order of potency (mean negative log EC50 value) was GTN greater than ISO greater than PBD = forskolin greater than adenosine. The relaxation responses to PBD and isobutyl methylaxanthine (IBMX) were not attenuated with removal of endothelial cells. In the femoral artery, methylene blue diminished GTN-induced relaxation but not PBD-induced relaxation. PBD and IBMX increased the relaxation responses of the artery to cyclic AMP-forming drugs (ISO, forskolin and adenosine) but not a cyclic GMP-forming drug (GTN). PBD and IBMX increased the relaxation response of mesenteric veins to ISO. The drugs noncompetitively inhibited arterial contractions accompanied by voltage-dependent and alpha-adrenoceptor-operated Ca2+ influxes. In the absence of extracellular Ca2+, PBD and IBMX reduced contractile responses of arteries to norepinephrine but not caffeine. The present results suggested that PBD relaxed the blood vessels, at least in part, through an intracellular accumulation of cyclic AMP.     

Relation between density (maximum binding) of alpha adrenoceptor binding sites and contractile response in four canine vascular tissues

In microsomal fractions from dog aorta, saphenous veins, mesenteric arteries and veins, both [3H]prazosin and [3H]rauwolscine displayed monophasic saturation in binding. The Kd for [3H] rauwolscine binding was similar for all these blood vessels, but the maximum number of [3H]rauwolscine binding sites was 3 to 7 times higher in veins compared to arteries. The Kd for [3H] prazosin was higher in saphenous vein than that in the arteries. The maximum number of binding sites for [3H]prazosin was similar, except for that in aorta, which was 3 times greater. Phenylephrine (alpha-1 adrenoceptor selective agonist) or norepinephrine (nonselective adrenoceptor agonist) produced similar maximal responses in all vessels. The alpha-2 adrenoceptor selective agonist, B-HT 920 (2-amino-6-allyl-3,4,7,8-tetrahydro-6H-thiazolo[5,4-d]-azepine)-induced contraction in veins but not in arteries. Prazosin (10(-6) M) inhibited completely the contractions to norepinephrine (3 x 10(-6) M) in mesenteric arteries and to phenylephrine (3 x 10(-6) M) in arteries and veins. Contractile responses of mesenteric artery were unaffected by rauwolscine. Rauwolscine (10(-7) M) caused a greater parallel rightward shift of the concentration-response curve to norepinephrine than did prazosin (10(-7) M) in saphenous veins, and a further rightward shift of responses to norepinephrine after 10(-7) M prazosin in mesenteric vein and saphenous vein and abolished B-HT 920-induced responses at alpha-2 adrenoceptors. The tissues responding to B-HT-920 correspond to those having the highest alpha-2 receptor density as measured by [3H]rauwolscine binding. The density of such sites required for contraction to be initiated in veins was much higher than with alpha-1 adrenoceptor sites.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of tertatolol on post- and prejunctional beta adrenoceptors

The effects of tertatolol, a new and powerful beta adrenoceptor blocking drug, on post- and prejunctional beta receptors were investigated; canine vascular tissues (saphenous veins, coronary arteries and splenic arteries) and guinea-pig trachea and atria were used. At concentrations below 10(-5) M, tertatolol did not alter basal tension or contractile responses to electrical stimulation, norepinephrine, K+ or prostaglandin F2 alpha; at doses at or above 10(-5) M the drug-evoked contractions which were reduced by phentolamine and were absent in denervated veins. Tertatolol at 10(-5) M and 3 X 10(-5) M augmented the basal efflux of [3H] norepinephrine in saphenous veins labeled with the 3H-transmitter. In veins, 10(-5) M of tertatolol depressed the contractions caused by electrical stimulation without affecting those to exogenous norepinephrine; this concentration of the drug also inhibited the stimulation-induced overflow of [3H]norepinephrine. The major part of the present study was designed to test the beta receptor blocking properties of tertatolol and to compare its effects with those of propranolol. Tertatolol inhibited, in a concentration-dependent manner, the relaxations caused by isoproterenol in saphenous veins, splenic arteries and coronary arteries and the relaxations evoked by norepinephrine and epinephrine in coronary arteries; the potency of tertatolol was higher than that of propranolol. In trachea and right atria of the guinea-pig, tertatolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol; the relative potency of tertatolol was higher than that of propranolol. In dog saphenous veins, previously incubated with [3H]norepinephrine, tertatolol (10(-7)M) blocked the increased stimulation-evoked overflow of the 3H-transmitter induced by isoproterenol.(ABSTRACT TRUNCATED AT 250 WORDS)     

Regulation of alpha-1 adrenergic receptor density and functional responsiveness in rat brain

The effects of changes in norepinephrine availability on alpha-1 adrenergic receptor density and responsiveness were determined in several regions of rat brain. Receptor density was determined from specific 125I-BE 2254 binding, and responsiveness was determined by norepinephrine-stimulated increases in inositol phosphate accumulation and in cyclic AMP accumulation in the absence or presence of adenosine in slices where beta adrenergic receptors had been inactivated. Adrenergic input was reduced by destroying noradrenergic neurons with DSP-4, depleting amines with chronic reserpine treatment or blocking alpha-1 adrenergic receptors with chronic prazosin treatment. All three treatments caused similar increases in alpha-1 adrenergic receptor density in cerebral cortex but not in striatum or hippocampus. DSP-4 treatment increased the maximal cyclic AMP response to both norepinephrine and phenylephrine but did not alter the maximal inositol phosphate response or the maximal potentiation of the cyclic AMP response to adenosine. DSP-4 treatment also increased the potency of norepinephrine in activating all three responses in cerebral cortex. Adrenergic input was increased by chronic treatment with desmethylimipramine to block norepinephrine reuptake, chronic i.c.v. infusion of norepinephrine or chronic yohimbine treatment to block presynaptic autoreceptors. None of these treatments caused significant changes in alpha-1 adrenergic receptor density or functional responsiveness in any region studied. The results suggest that alpha-1 adrenergic receptor density and responsiveness in rat brain can be increased but not easily decreased. They also suggest that different brain regions are affected differently by alterations of adrenergic input and that the different responses are not coregulated.     

Influence of age on control of norepinephrine release from the rat tail artery.

Stimulation-evoked norepinephrine release from the rat tail artery increases with age; therefore, the sensitivity of prejunctional alpha-2 adrenergic receptors to antagonists and agonists was compared in perfused tail arteries from Fischer-344 rats, aged 6 and 20 months. The increase in endogenous fractional norepinephrine release produced by blockade of alpha-2 adrenergic receptors with submaximal concentrations of either yohimbine or idazoxan was significantly greater in 6-month-old animals as compared to 20 months; however, the effect of a maximal concentration of idazoxan was not significantly different. Inhibition of norepinephrine release by the alpha-2 receptor agonist UK14304 was reduced in 20-month-old animals compared to 6 months. In contrast, there were no age-related differences in inhibition of contractile responses to nerve stimulation by the prejunctionally acting dopamine D2 agonist, N-0923. These data suggest that age-related changes in the sensitivity of prejunctional alpha-2 receptors to agonists and antagonists may not reflect any fundamental alteration in the function of this receptor system, but may be related to competition between alpha-2 agonists or antagonists and increased biophase concentrations of norepinephrine. This conclusion is supported by lack of an age-related change in function of prejunctional dopamine D2 receptors. Persistence of age-related increases in norepinephrine release when alpha-2 adrenergic receptors are fully blocked may reflect an alteration in other fundamental mechanisms that control norepinephrine release.     

Actions of the alpha-1 adrenoceptor blocker bunazosin on the norepinephrine-induced contraction of smooth muscles in the rabbit proximal urethra

Effects of bunazosin on the norepinephrine-induced electrical and mechanical activities of smooth muscles of the rabbit proximal urethra were investigated using microelectrode and tension recording methods. Responses to norepinephrine were mediated by activation of both alpha-1 and beta adrenoceptors. In the presence of propranolol, the norepinephrine-induced contraction increased and, with yohimbine, the phasic but not tonic contraction was only inhibited slightly. Contributions of the alpha-2 adrenoceptor to the norepinephrine-induced contraction were negligible. Bunazosin inhibited in a concentration-dependent manner both the phasic and tonic responses of the norepinephrine-induced contraction, and the concentration-response relationship for norepinephrine shifted to the right. The Schild plot obtained from measurements of tonic responses in this antagonism yielded a straight line with a slope of 0.96. The pA2 value for bunazosin was 8.39 and the KB value was 4.1 nM. Prazosin had similar effects (the corresponding values being 0.96, 8.21 and 6.2 nM, respectively). The mechanical response evoked by field stimulation was composed of cholinergic, noradrenergic alpha-1 and noncholinergic-nonadrenergic contractions and of a subsequent nonadrenergic-noncholinergic relaxation. Bunazosin inhibited the twitch contraction evoked by field stimulation more than did prazosin, albeit not completely. These results indicate that although the smooth muscle tone in the urethra is regulated by multiple neural factors, the elevation of the tone is regulated predominantly by activation of the alpha-1 adrenoceptors. Bunazosin has an antagonistic action on this receptor. The actions of bunazosin are discussed in relation to the clinical application in cases of inadequate micturition.     

Beta adrenoceptor subtype in isolated human, monkey and dog epicardial coronary arteries

Isolated human, Japanese monkey and dog epicardial coronary arteries and dog renal and mesenteric arteries treated with phentolamine responded to isoproterenol with a concentration-related relaxation. The KB values of metoprolol, a beta-1 antagonist, in the coronary arteries from different mammals did not differ, but were appreciably smaller than those in the dog renal and mesenteric arteries. Treatment with butoxamine, a beta-2 antagonist, inhibited the relaxation of dog mesenteric arteries to a greater extent than that of monkey and dog coronary arteries. Terbutaline, a beta-2 agonist, produced a greater relaxation in monkey mesenteric and dog renal and mesenteric arteries than in human, monkey and dog coronary arteries. Norepinephrine relaxed the monkey and dog coronary arteries dose-dependently via mainly beta-1 adrenoceptors, but elicited a contraction or a minute relaxation in dog mesenteric arteries even when treated with high concentrations of phentolamine. Contractile responses to electrical stimulation of adrenergic nerves in monkey coronary arteries were potentiated by treatment with metoprolol and propranolol, whereas the contractions in dog mesenteric arteries were unaffected. It is concluded that the amine-induced relaxation of human and monkey epicardial coronary arteries is mediated mainly by beta-1 adrenoceptor subtype, as is the response of dog coronary arteries. Involvement of beta-1 subtype in coronary artery relaxations would be a mechanism underlying potentiation by beta antagonists of the contraction caused by norepinephrine released from adrenergic nerves in primates.     

Interaction between alpha adrenergic and serotonergic activation of canine saphenous veins.

Serotonin and norepinephrine produced concentration-dependent contractions of helical strips of canine saphenous veins. The contractile responses to both agonists were inhibited by the alpha adrenergic receptor blocking agent phentolamine. Tolazoline inhibited the contractile responses of canine saphenous veins to norepinephrine but augmented those to serotonin. Blockade of adrenergic neuronal reuptake with cocaine enhanced the sensitivity of the canine saphenous vein to serotonin, but did not suppress the inhibition by phentolamine of the contractile responses to this indolealkylamine. Serotonin-mediated venoconstriction was not secondary to release of norepinephrine since it was not accompanied by an increased release of [7-3H]-norepinephrine. These findings suggest that serotonin does not contract canine saphenous veins by stimulation of typical serotonergic receptors. The binding sites for serotonin and norepinephrine in cutaneous venous smooth muscle may share part of a common receptor complex, which triggers the contractile process. Alternatively, serotonin and norepinephrine may act at two different receptors to elicit contraction of canine saphenous veins.     

Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein

We observed the effects of carvedilol, a novel beta adrenoceptor blocker, on electrical responses of smooth muscle cells produced by endogenous and exogenous norepinephrine (NE) in isolated canine mesenteric artery and vein. Carvedilol inhibited the NE-induced depolarization in the artery but not in vein, with potencies equivalent to prazosin, i.e., carvedilol blocked alpha 1 adrenoceptors in arterial smooth muscles. Stimulation of perivascular nerves evoked an excitatory junction potential (e.j.p.) and a slow depolarization in these vascular smooth muscles. Carvedilol inhibited the slow depolarization evoked in the artery but not in the vein, with no marked inhibition of the e.j.p.s. High concentrations (10(-5) M) of carvedilol inhibited the e.j.p., slow depolarization, and also the compound action potentials of sympathetic nerve bundles running along the mesenteric vessels, suggesting that these inhibitions were due to local anesthetic actions. The e.j.p. amplitude was increased by isoprenaline and was decreased by NE. The NE and isoprenaline actions were antagonized by yohimbine and propranolol, respectively. Carvedilol inhibited the isoprenaline-actions but not the NE actions on the e.j.p., suggesting that this drug blocked prejunctional beta adrenoceptors but not the alpha 2 adrenoceptors. These results indicate that carvedilol blocks alpha 1 and beta adrenoceptors but not alpha 2 adrenoceptors in vascular tissues.     

Mechanisms of endothelin-induced venoconstriction in isolated guinea pig mesentery

In the present study, endothelin (ET) agonists and receptor selective antagonists were used to characterize ET receptors mediating constriction in guinea pig mesenteric veins (250-300 micrometers diameter) in vitro. The contribution of ET-evoked vasodilator release to venous tone was also explored. Computer-assisted video microscopy was used to monitor vein diameter. Endothelin-1 (ET-1), endothelin-3 (ET-3), and sarafotoxin 6c (S6c) produced sustained concentration-dependent contractions with a rank order agonist potency of ET-1 = S6c > ET-3. Indomethacin (1 microM) and Nomega-nitro-L-arginine (100 microM) enhanced ET-1 and S6c responses. The ETA selective antagonists BQ-610 (100 nM) and PD156707 (10 nM) shifted ET-1 concentration-response curves rightward and decreased maximal ET-1 responses, without changing S6c responses. The ETB selective antagonist BQ-788 (100 nM) shifted S6c responses rightward but produced no change in ET-1 responses. Combined application of BQ-788 and BQ-610 or BQ-788 and PD 156707 produced a rightward shift in ET-1 responses that was greater than shifts produced by BQ-610 or PD 156707 alone. In conclusion, smooth muscle in guinea pig mesenteric veins expresses ETA and ETB receptors coupled to contractile mechanisms. Activation of endothelial ETB receptors results in release of vasodilators, primarily nitric oxide.     

Role of endothelium on the effects of neuropeptide Y in mesenteric resistance arteries of spontaneously hypertensive and Wistar-Kyoto normotensive rats

The role of the endothelium in the effects of neuropeptide Y (NPY) and norepinephrine was investigated in mesenteric resistance arteries of the spontaneously hypertensive rat (SHR) and of the normotensive Wistar-Kyoto rat (WKY). Endothelium-dependent relaxation to acetylcholine (1 microM) was reduced in arteries of SHR compared with WKY. In the presence of the endothelium, the vessels of the two strains responded similarly to norepinephrine and NPY (100 nM) produced only a slight contraction. After removal of the endothelium, the response to norepinephrine was greater in WKY than in SHR. Furthermore, endothelium denudation enhanced markedly contraction elicited by NPY in WKY (up to 40% of the maximal effect of norepinephrine), but not in SHR. NPY potentiated the contractile response to low concentrations of norepinephrine (less than 300 nM) in both strains regardless whether the endothelium was intact or not. These results indicate that the contractile responses to NPY and to norepinephrine are inhibited by the endothelium in vessels of WKY, but not in those of the SHR. Furthermore, the potentiating effect of NPY occurs via an endothelium-independent mechanism in mesenteric arteries of both SHR and WKY. It is proposed that the differential responses between the two strains are related to abnormal function of the endothelium and to decreased responsiveness of smooth muscle cells in mesenteric resistance arteries of SHR compared to WKY.     

Responses of saphenous and mesenteric veins to administration of dopamine

Others have observed that dopamine (3,4-dihydroxyphenylethylamine) constricts resistance vessels in skin, but dilates these vessels in the mesentery. We studied the effects of dopamine on cutaneous and mesenteric veins of dogs to see if this agent also produced qualitatively different effects on the tone of capacitance vessels (veins) in these vascular beds. The lateral saphenous or the left colic vein was perfused at constant flow with blood from a femoral artery. Pressures at the tip of the perfusion cannula and at the tip of a catheter 15 cm downstream were recorded continuously. Increases in the pressure gradient between these two points indicated venoconstriction; decreases indicated venodilatation. Dopamine and norepinephrine injected into the perfusion tubing caused constriction of both veins. The constriction was antagonized by blockade of alpha receptors. A dilator action of dopamine was not seen, even after alpha receptor blockade or in the presence of increased venous tone produced by serotonin, norepinephrine, or nerve stimulation. Reserpine and cocaine did not alter responses to dopamine in the saphenous vein; this suggests that the venoconstrictor action of dopamine results mainly from a direct effect on alpha receptors and that uptake into sympathetic nerve endings may not be important in regulating the amount of dopamine available to receptors in the saphenous vein.     

Calcitonin gene-related peptide is the endogenous mediator of nonadrenergic-noncholinergic vasodilation in rat mesentery

In the isolated perfused rat mesenteric vascular bed pretreated with guanethidine and precontracted with methoxamine, periarterial nerve stimulation elicited a frequency-dependent and endothelium-independent vasodilation. The sustained vasodilation was slow-onset and reversible. It was resistant to propranolol or atropine but sensitive to tetrodotoxin and capsaicin suggesting that this is a nonadrenergic-noncholinergic vasodilation and is a neurogenic response. The vasodilation was abolished by anti-serum against calcitonin-gene related peptide (CGRP) in a concentration-dependent manner. These data suggest that the non-adrenergic-noncholinergic vasodilation is mediated by endogenous CGRP released from the primary sensory nerve terminals upon electrical stimulation. In addition to the vasodilator action, CGRP also inhibited nerve stimulation-induced and norepinephrine-induced vasoconstriction at extremely low concentrations. The inhibitory action of CGRP appeared to be mediated by postsynaptic mechanisms inasmuch as evoked norepinephrine release was not affected by CGRP when the vasoconstriction produced by norepinephrine or periarterial nerve stimulation was attenuated greatly by CGRP. These observations suggest that the vascular tone of the resistance vessels can be regulated by primary sensory nerve-derived CGRP.     

Beta adrenoceptor mediation of the enhancing effect of norepinephrine on the murine primary antibody response in vitro

The beta adrenoceptor has been identified in this study to be the receptor responsible for the enhanced immunoglobulin M antibody response produced by norepinephrine in mouse spleen cells immunized with sheep erythrocytes in vitro. The magnitude and kinetics of the enhanced antibody response to norepinephrine alone, or to norepinephrine in the presence of phentolamine, were more closely mimicked with a beta-2 adrenoceptor agonist (terbutaline) than with a beta-1 adrenoceptor agonist (dobutamine). Norepinephrine alone, norepinephrine in the presence of phentolamine, or terbutaline exposure produced a number of spleen cells secreting immunoglobulin M antibody that is equal to control on day 4 after immunization and which is enhanced above control on days 5, 6 and 7. Dobutamine causes no change when compared to control on days 4 and 5, but causes a delayed decline in the response on days 6 and 7. All drug responses were concentration-dependent and propranolol antagonized the enhanced response observed in the presence of terbutaline or dobutamine alone. When norepinephrine was added to immunized spleen cell cultures in the presence of propranolol, an alpha adrenoceptor-mediated component was unmasked which produced an enhanced response on day 4 after immunization and returned to control levels on days 5, 6 and 7. These results suggest that antibody responses can be modulated positively by a sympathetic neurotransmitter. This up-modulation by norepinephrine is beta adrenoceptor-mediated at the time of, and after, peak control response and alpha adrenoceptor-mediated 1 day before peak control response.     

Contractile actions of racemic and d-propranolol on isolated canine mesenteric and coronary arteries

This investigation was undertaken to determine whether propranolol exerts a direct vasoconstriction action which contributes to the increased systemic and regional vascular resistance observed after its acute administration. Helically cut strips of canine mesenteric and coronary arteries were exposed to cumulative concentrations of racemic propranolol, d-propranolol, metoprolol and sotalol. Racemic and d-propranolol were equipotent in eliciting concentration-related increments in tension in the mesenteric (3 x 10(-6)-3 x 10(-5) M) and coronary (3 x 10(-7)-3 x 10(-5) M) arterial strips. Metoprolol and sotalol did not cause contractions in concentrations up to 10(-4) M. Phenoxybenzamine, 10-(-6) M, did not alter the contractile responses elicited by racemic and d-propranolol. Upon exposure of mesenteric strips to calcium-free media or 10(-6) M verapamil, the contractile responses to propranolol (3 x 10(-5) M) and KCl (30 mM) were markedly reduced (not significantly different), whereas norepinephrine (10(-6) M)-induced responses were inhibited to a significantly lesser degree. In coronary arteries exposed to calcium-free media or 10(-6) M verapamil, the responses to propranolol, KCl and methoxamine (10(-5) M) were all extensively decreased (not significantly different). These results indicate that propranolol exerts a direct contractile effect on canine mesenteric and coronary arteries, which is unrelated to its beta adrenergic blocking activity and is not mediated through action on alpha adrenergic receptors. The propranolol-induced contraction appears to be associated predominantly with an influx of calcium ion.     

Dopamine inhibits vasopressin action in the rat inner medullary collecting duct via alpha(2)-adrenoceptors

We compared the effects of dopamine and norepinephrine on vasopressin (AVP)-stimulated increases in osmotic water permeability (Pf) and cAMP accumulation in the rat inner medullary collecting duct (IMCD). Both dopamine and norepinephrine inhibited AVP-induced Pf and cAMP accumulation in a concentration-dependent manner; however, norepinephrine was approximately 100-fold more potent than dopamine. The effects of dopamine on Pf were antagonized by the selective alpha(2)-adrenoceptor antagonist, rauwolscine (10 nM--1 microM). Clozapine (10 microM), a dopamine D(4) receptor antagonist with significant activity at adrenergic receptors, partially attenuated both dopamine and norepinephrine-induced decreases in AVP-stimulated Pf. Dopamine-induced inhibition of AVP-dependent cAMP levels was antagonized by the alpha(2)-adrenoceptor antagonists, rauwolscine, idazoxan, and yohimbine, but not by the dopamine receptor antagonists, spiperone, SCH-23390, or raclopride. Clozapine (1--10 microM) inhibited the effects of both dopamine and norepinephrine on AVP-stimulated cAMP levels. We conclude that the inhibitory effects of dopamine on AVP-induced Pf and cAMP accumulation in the rat IMCD are mediated via alpha(2)-adrenoceptors.     

Nifedipine and alpha adrenoceptors in rat aorta. II. Role of extracellular calcium in enhanced alpha-2 adrenoceptor-mediated contraction in diabetes

The mechanism responsible for increased norepinephrine-induced responsiveness of aortas isolated from streptozotocin-diabetic rats compared to age-matched control animals was investigated. Selective alpha-1 and alpha-2 adrenoceptor agonists and antagonists were used to determine the contribution of these receptor subtypes to the norepinephrine-induced contractile response. Findings from these experiments indicated an enhancement of alpha-2 adrenoceptor-mediated contraction in aortas from diabetic rats, whereas alpha-1-mediated responses were not altered. The contribution of extracellular calcium influx to the agonist-induced contractions was determined by using the calcium entry blocker nifedipine. Contractile responses to maximally effective concentrations of norepinephrine, phenylephrine and clonidine were separated into fast and slow components and the effect of increasing concentrations of nifedipine on the responses was determined. These experiments indicated that the fast component of contraction to alpha adrenoceptor agonists was insensitive to nifedipine treatment, whereas the slow component was inhibited effectively. The slow component of contraction in response to norepinephrine and clonidine in aortas from diabetic rats was increased significantly compared to control tissues. These results suggest that there is an increase in alpha-2 adrenoceptor activity in aortas from diabetic rats. Furthermore, the increased aortic contractile responses induced by norepinephrine and selective alpha-2 agonists are due probably to an increased influx of extracellular calcium through nifedipine-sensitive ion channels associated with activation of alpha-2 adrenoceptors.     

Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.

We have shown recently that norepinephrine stimulates muscle cell hypertrophy in primary cultures from the neonatal rat ventricle and that this stimulation is not blocked by the beta adrenergic antagonist propranolol. The present study was done to define the adrenergic specificity of the myocyte hypertrophic response to norepinephrine. 90% pure, single-cell cultures of nongrowing myocytes were maintained in serum-free medium 199 with transferin and insulin. Myocyte size was quantitated 48 h after addition of adrenergic agents, by measuring cell volume, cell surface area, and cell protein. L-norepinephrine increased myocyte size to a maximum 150% of control; half-maximum effect was obtained at a concentration of 0.2 microM. This increase in cell size was inhibited by the nonselective alpha adrenergic antagonist phentolamine and by the alpha 1 adrenergic antagonists prazosin and terazosin; it was not inhibited by propranolol or by the alpha 2 adrenergic antagonist yohimbine. The beta adrenergic agonist isoproterenol did not increase cell size. Thus, norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.